S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:LPCN

Lipocine - LPCN Stock Forecast, Price & News

$0.53
+0.01 (+1.91%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.49
▼
$0.56
50-Day Range
$0.39
▼
$0.58
52-Week Range
$0.36
▼
$1.89
Volume
118,330 shs
Average Volume
119,180 shs
Market Capitalization
$47.32 million
P/E Ratio
13.37
Dividend Yield
N/A
Price Target
$4.00

Lipocine MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
648.2% Upside
$4.00 Price Target
Short Interest
Bearish
1.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Lipocine in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$10,217 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.13) to ($0.11) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

899th out of 1,055 stocks

Pharmaceutical Preparations Industry

446th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

LPCN stock logo

About Lipocine (NASDAQ:LPCN) Stock

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

January 24, 2023 | americanbankingnews.com
Lipocine (NASDAQ:LPCN) Receives New Coverage from Analysts at StockNews.com
January 16, 2023 | finance.yahoo.com
Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 5, 2023 | finance.yahoo.com
Lipocine to Present at Biotech Showcase
December 19, 2022 | finance.yahoo.com
Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis
November 9, 2022 | finance.yahoo.com
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022
November 3, 2022 | finance.yahoo.com
Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline
October 11, 2022 | finance.yahoo.com
Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference - Yahoo Finance
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
October 11, 2022 | finance.yahoo.com
Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference
September 27, 2022 | finance.yahoo.com
Lipocine to Participate in the Cantor Neurology & Psychiatric Conference
September 27, 2022 | seekingalpha.com
Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% - Seeking Alpha
September 26, 2022 | finance.yahoo.com
Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets
September 26, 2022 | finance.yahoo.com
Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders
September 23, 2022 | finance.yahoo.com
Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference - Yahoo Finance
September 22, 2022 | finance.yahoo.com
Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference
September 16, 2022 | finance.yahoo.com
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) - Yahoo Finance
September 15, 2022 | nasdaq.com
Lipocine Announces Favorable Regulatory Pathway On LPCN 1154 For Post-Partum Depression - Nasdaq
September 15, 2022 | benzinga.com
Lipocine (NASDAQ:LPCN) – Lipocine Announces Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depressi - Benzinga
September 15, 2022 | finance.yahoo.com
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)
August 10, 2022 | finance.yahoo.com
LPCN: TLANDO Launched
August 9, 2022 | finance.yahoo.com
Lipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
August 8, 2022 | apnews.com
Lipocine: Q2 Earnings Snapshot
August 8, 2022 | benzinga.com
Recap: Lipocine Q2 Earnings - Benzinga
August 8, 2022 | streetinsider.com
Form 10-Q Lipocine Inc. For: Jun 30 - StreetInsider.com
August 8, 2022 | seekingalpha.com
Lipocine GAAP EPS of -$0.04 in-line, revenue of $0.5M beats by $0.24M (NASDAQ:LPCN) - Seeking Alpha
August 8, 2022 | streetinsider.com
Form 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com
See More Headlines
Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings
11/09/2022
Today
1/28/2023
Next Earnings (Estimated)
3/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPCN
CUSIP
N/A
CIK
1535955
Web
www.lipocine.com
Phone
(801) 994-7383
Fax
801-994-7388
Employees
13
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+648.2%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.04
Trailing P/E Ratio
13.37
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-630,000.00
Net Margins
N/A
Pretax Margin
24.69%
Return on Equity
9.90%
Return on Assets
9.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
23.90
Quick Ratio
23.90

Sales & Book Value

Annual Sales
$16.14 million
Price / Sales
2.93
Cash Flow
$0.05 per share
Price / Cash Flow
11.83
Book Value
$0.52 per share
Price / Book
1.03

Miscellaneous

Outstanding Shares
88,510,000
Free Float
83,908,000
Market Cap
$47.32 million
Optionable
Optionable
Beta
0.60

Social Links


Key Executives

  • Mahesh V. PatelMahesh V. Patel
    President, Chief Executive & Financial Officer
  • George G Nomikos
    Chief Medical Officer
  • Anthony DelConte
    Chief Medical Director
  • Nachiappan Chidambaram
    Vice President-Product Development
  • Krista Fogarty
    Chief Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?

0 analysts have issued 12 month price objectives for Lipocine's shares. Their LPCN share price forecasts range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 648.2% from the stock's current price.
View analysts price targets for LPCN or view top-rated stocks among Wall Street analysts.

How have LPCN shares performed in 2023?

Lipocine's stock was trading at $0.3978 at the beginning of 2023. Since then, LPCN stock has increased by 34.4% and is now trading at $0.5346.
View the best growth stocks for 2023 here.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our LPCN earnings forecast.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) announced its earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03).

What other stocks do shareholders of Lipocine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX).

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $0.53.

How much money does Lipocine make?

Lipocine (NASDAQ:LPCN) has a market capitalization of $47.32 million and generates $16.14 million in revenue each year. The specialty pharmaceutical company earns $-630,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 1/28/2023 by MarketBeat.com Staff